Celsense

 

 

NEWS RELEASE - For Immediate Release

Celsense, Inc. CSO to Speak at Stem Cell Conference

September 14, 2006 - Pittsburgh, Pennsylvania

Celsense, Inc, a leading provider of molecular and cellular imaging solutions, today announced that its Chief Scientific Officer Eric T. Ahrens would be presenting at the 6th Annual Stem Cells and Regenerative Medicine Conference on October 17, 2006. The conference, presented by the Strategic Research Institute, will be held in Pittsburgh October 16 and 17. “This is the first time that Celsense will make a public presentation regarding its product and technology set. We are delighted that Eric will be appearing at this very prestigious conference,” said Charlie O’Hanlon, Chief Executive Officer of Celsense.

The abstract for Dr. Ahrens presentation is presented below:

Standardized solutions for non-invasive imaging of therapeutic cells post-transfer

A limiting factor for the developers of cellular therapies is an inability to non-invasively visualize the delivery and migration of cells in a patient. In this talk we will describe a unique non-invasive imaging platform for visualizing and quantifying a specific cell population in vivo. This technology utilizes novel fluorine-based MRI tracer agents. The platform can be used to visualize the delivery and trafficking of a wide range of emerging cellular therapeutics such as stem cells. Visualization and quantification of sites of inflammation is another key application. Exemplary data using this technology as an in vivo quantitative biomarker in rodent models will be presented, as well as the pathway for clinical translation.


About Celsense, Inc. Celsense is a Pittsburgh based biotechnology company offering products that enable the real-time in vivo imaging of the administration of cells transplanted for therapeutic and diagnostic purposes, using conventional MRI. The mission of the company is to be the worldwide leader in anticipating and meeting the needs of developers of therapeutics to image transplanted cells and gene expression in vivo.

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.
(412)263-2870
charlie@celsense.com